{
    "answer": "The Novartis Q4 2024 Condensed Financial Report showed Cosentyx's revenue as USD 6.1 billion, with a +23% growth. However, this report focuses on general \"Entresto and Cosentyx\" performance and does not specify immunology segment details or year-over-year changes on reported or constant currency basis for full year 2024 or 2023. The Novartis 2024 Annual Report/Society Integrated Report provided total company full-year net sales figures but did not contain specific immunology segment metabolic data for comparison.",
    "ground_truth": "$6,141,000,000; 23% increase (reported); 25% increase (constant currency)",
    "rewards": [
        0,
        0,
        0,
        0,
        0,
        0,
        0,
        0
    ],
    "reward_sum": 0,
    "turns": 8,
    "search count": 7,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        935,
        2526,
        3963,
        5240,
        6729,
        8113,
        9969,
        11532
    ]
}